Factor | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
P value | OR (95% CI) | P value | OR (95% CI) | |
Gender | ||||
Male | ||||
Female | 0.649 | 0.80 (0.30–2.12) | ||
Age (years) | ||||
≤ 65 | ||||
> 65 | 0.146 | 0.42 (0.13–1.36) | ||
T stage in naïve | ||||
T1–2 | ||||
T3–4 | 0.099 | 2.36 (0.85–6.55) | ||
Type of mutation | ||||
Exon 19-del | 0.080 | |||
Exon 21 L858R | 0.141 | 0.45 (0.16–1.3) | ||
Others | 0.219 | 3.00 (0.52–17.32) | ||
Type of EGFR-TKI | ||||
Gefitinib | 0.081 | 0.081 | ||
Erlotinib | 0.641 | 0.76 (0.24–2.39) | 0.808 | 1.18 (0.32–4.37) |
Icotinib | 0.025 | 0.09 (0.01–0.74) | 0.030 | 0.08 (0.007–0.78) |
The treatment model | ||||
Simultaneous EGFR-TKI and TRT for first line | 0.448 | |||
Simultaneous EGFR-TKI, chemotherapy and TRT for first line | 0.384 | 1.76 (0.49–6.34) | ||
Previous chemotherapy, simultaneous EGFR-TKI and TRT for second line | 0.206 | 2.50 (0.60–10.34) | ||
Dose fractionation | ||||
CFRT | ||||
SBRT | 0.558 | 1.70 (0.29–9.97) | ||
GTV (ml) | ||||
≤ 27 | ||||
> 27 | 0.045 | 2.77 (1.02–7.49) | ||
PTV (ml) | ||||
≤ 120 | ||||
> 120 | 0.009 | 4.03 (1.42–11.43) | ||
Dose per fraction (Gy) | ||||
< 3.00 | ||||
≥ 3.00 | 0.039 | 0.29 (0.09–0.94) | ||
Total dose (Gy) | ||||
≤ 50 | ||||
> 50 | 0.752 | 0.85 (0.30–2.38) | ||
Total dose EQD2 (α/β = 3) (Gy) | ||||
≤ 55 | ||||
> 55 | 0.103 | 0.42 (0.15–1.19) | ||
Overlap time of EGFR-TKI and TRT (days) | ||||
≤ 20 | ||||
> 20 | 0.008 | 8.52 (1.75–41.41) | 0.011 | 9.11 (1.67–49.65) |
Duration of TRT (days) | ||||
≤ 33 | ||||
> 33 | 0.048 | 3.05 (1.01–9.21) | ||
Ipsilateral lung V30 (%) | ||||
≤ 34 | ||||
> 34 | 0.015 | 7.50 (1.48–38.08) | 0.036 | 7.48 (1.14–49.14) |
Timing of TRT was added | ||||
TRT was added after the PD in the maintain of TKI | ||||
TRT was added without PD in the maintain of TKI | 0.631 | 1.32 (0.43–4.06) |